ANNX.ST
Annexin Pharmaceuticals AB (publ) [ANNX.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ANNX.ST Stock Summary
In the News
ANNX.ST Financial details
Company Rating
Neutral
Market Cap
95.31M
Income
-44.06M
Revenue
0
Book val./share
0.05
Cash/share
0.06
Dividend
-
Dividend %
-
Employees
4
Optionable
No
Shortable
Yes
Earnings
29 Oct 2020
P/E
-1.11
Forward P/E
-
PEG
1.09
P/S
-
P/B
2.29
P/C
4.58
P/FCF
-1.08
Quick Ratio
4.65
Current Ratio
5.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.15
EPS next Y
-
EPS next Q
-
EPS this Y
52.94%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
3.45%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-169%
ROE
-144%
ROC
-2.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.183571-0.751249
52W High
-
52W Low
-
RSI
57
Rel Volume
0.26
Avg Volume
397.9K
Volume
104.19K
Perf Week
3%
Perf Month
-0.36%
Perf Quarter
-32.6%
Perf Half Y
-60.71%
-
-
-
-
Beta
1.045
-
-
Volatility
0.01%, 0.01%
Prev Close
0.36%
Price
0.275
Change
-1.08%
ANNX.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.57 | -0.39 | -0.39 | -0.17 | -0.26 | |
| Operating cash flow per share | -0.52 | -0.34 | -0.33 | -0.17 | -0.26 | |
| Free cash flow per share | -0.52 | -0.34 | -0.33 | -0.17 | -0.26 | |
| Cash per share | 0.09 | 0.16 | 0.37 | 0.13 | 0.13 | |
| Book value per share | 0.23 | 0.18 | 0.35 | 0.12 | 0.11 | |
| Tangible book value per share | 0.22 | 0.17 | 0.34 | 0.12 | 0.11 | |
| Share holders equity per share | 0.23 | 0.18 | 0.35 | 0.12 | 0.11 | |
| Interest debt per share | 0.01 | 0 | 0.01 | 0 | 0 | |
| Market cap | 57.8M | 202.17M | 135.42M | 240.97M | 43.45M | |
| Enterprise value | 53.76M | 184.03M | 85.94M | 209.86M | 22.03M | |
| P/E ratio | -2.04 | -4.52 | -2.55 | -5.92 | -0.99 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -2.25 | -5.16 | -3.01 | -5.85 | -1 | |
| PFCF ratio | -2.25 | -5.16 | -3.01 | -5.85 | -1 | |
| P/B Ratio | 5.03 | 9.8 | 2.9 | 7.99 | 2.31 | |
| PTB ratio | 5.03 | 9.8 | 2.9 | 7.99 | 2.31 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -1.9 | -4.21 | -1.71 | -5.15 | -0.5 | |
| EV to operating cash flow | -2.09 | -4.69 | -1.91 | -5.1 | -0.51 | |
| EV to free cash flow | -2.09 | -4.69 | -1.91 | -5.1 | -0.51 | |
| Earnings yield | -0.49 | -0.22 | -0.39 | -0.17 | -1.01 | |
| Free cash flow yield | -0.45 | -0.19 | -0.33 | -0.17 | -1 | |
| Debt to equity | 0.02 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.01 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.14 | 0.41 | 0.98 | 0.76 | 0.49 | |
| Current ratio | 3.01 | 5.07 | 8.37 | 5.16 | 3.13 | |
| Interest coverage | -858.42 | -86.95 | -27.56 | -20.36K | 0 | |
| Income quality | 0.91 | 0.9 | 0.88 | 1.01 | 0.99 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.05 | 0.03 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.73 | 1.26 | 1.74 | 0.69 | 0.82 | |
| ROIC | -2.42 | -2.14 | -1.12 | -1.34 | -2.34 | |
| Return on tangible assets | -1.86 | -1.83 | -1.02 | -1.12 | -1.67 | |
| Graham Net | 0 | 0.12 | 0.33 | 0.11 | 0.09 | |
| Working capital | 9.13M | 18.38M | 44.66M | 27.12M | 16.97M | |
| Tangible asset value | 10.71M | 19.96M | 46.15M | 29.68M | 18.44M | |
| Net current asset value | 9.13M | 18.38M | 44.66M | 27.12M | 16.97M | |
| Invested capital | 0.02 | 0 | 0 | 0 | 0 | |
| Average receivables | 133K | 274K | 648.5K | 1.44M | 2.25M | |
| Average payables | 2.78M | 2.65M | 3.21M | 3.42M | 3.83M | |
| Average inventory | 4.28K | 6.42K | 2.14K | 0.5 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 4.55K | 5.48K | 6.67K | 6.3K | 8.18K | |
| Days of inventory on hand | 16.19 | 8.09 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.08 | 0.07 | 0.05 | 0.06 | 0.04 | |
| Inventory turnover | 22.54 | 45.09 | 192K | 0 | 0 | |
| ROE | -2.47 | -2.17 | -1.14 | -1.35 | -2.34 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.04 | -0.04 | -0.03 | -0.04 | -0.04 | |
| Operating cash flow per share | -0.05 | -0.04 | -0.03 | -0.04 | -0.04 | |
| Free cash flow per share | -0.05 | -0.04 | -0.03 | -0.04 | -0.04 | |
| Cash per share | 0.12 | 0.08 | 0.06 | 0.04 | 0.06 | |
| Book value per share | 0.12 | 0.08 | 0.04 | 0 | 0.05 | |
| Tangible book value per share | 0.12 | 0.07 | 0.04 | 0 | 0.05 | |
| Share holders equity per share | 0.12 | 0.08 | 0.04 | 0 | 0.05 | |
| Interest debt per share | 0 | 0 | 0 | 0.04 | 0 | |
| Market cap | 254.5M | 292.55M | 245.8M | 197.71M | 90.11M | |
| Enterprise value | 223.39M | 272.11M | 228.52M | 196.4M | 68.7M | |
| P/E ratio | -6.29 | -7.24 | -7.17 | -4.56 | -1.55 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -21.68 | -25.12 | -30.1 | -18.01 | -7.14 | |
| PFCF ratio | -21.68 | -25.12 | -30.1 | -18.01 | -7.14 | |
| P/B Ratio | 8.44 | 14.6 | 21.43 | 311.35 | 4.79 | |
| PTB ratio | 8.44 | 14.6 | 21.43 | 311.35 | 4.79 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -22.07 | -26.94 | -27.07 | -18.32 | -4.63 | |
| EV to operating cash flow | -19.03 | -23.37 | -27.98 | -17.9 | -5.44 | |
| EV to free cash flow | -19.03 | -23.37 | -27.98 | -17.9 | -5.44 | |
| Earnings yield | -0.04 | -0.03 | -0.03 | -0.05 | -0.16 | |
| Free cash flow yield | -0.05 | -0.04 | -0.03 | -0.06 | -0.14 | |
| Debt to equity | 0 | 0 | 0 | 15.75 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0.63 | 0 | |
| Net debt to EBITDA | 3.07 | 2.02 | 2.05 | 0.12 | 1.44 | |
| Current ratio | 5.16 | 5.11 | 1.83 | 0.92 | 3.13 | |
| Interest coverage | 10.12K | -10.1K | 0 | -94.89 | 0 | |
| Income quality | 1.16 | 1.15 | 0.95 | 1.02 | 0.87 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.32 | 0.25 | 0.18 | 0.05 | 0.23 | |
| ROIC | -0.33 | -0.5 | -0.75 | -1 | -0.79 | |
| Return on tangible assets | -0.28 | -0.42 | -0.38 | -0.7 | -0.55 | |
| Graham Net | 0.1 | 0.06 | 0.03 | -0.01 | 0.04 | |
| Working capital | 27.12M | 18.05M | 9.53M | -1.26M | 16.97M | |
| Tangible asset value | 29.68M | 19.59M | 11.05M | 238K | 18.44M | |
| Net current asset value | 27.12M | 18.05M | 9.53M | -1.26M | 16.97M | |
| Invested capital | 0 | 0 | 0 | 15.75 | 0 | |
| Average receivables | 936K | 1.6M | 2.25M | 2.79M | 2.53M | |
| Average payables | 3.8M | 1.97M | 2.02M | 2.89M | 3.35M | |
| Average inventory | -5K | 0 | 0 | 500 | 500 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 6.24K | 0 | 6.4K | 4.45K | 8.11K | |
| Days of inventory on hand | 0 | 0 | 0 | 1.88 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0 | 0.01 | 0.02 | 0.01 | |
| Inventory turnover | 0 | 0 | 0 | 48 | 0 | |
| ROE | -0.34 | -0.5 | -0.75 | -17.06 | -0.77 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ANNX.ST Frequently Asked Questions
What is Annexin Pharmaceuticals AB (publ) stock symbol ?
Annexin Pharmaceuticals AB (publ) is a SE stock and trading under the symbol ANNX.ST
What is Annexin Pharmaceuticals AB (publ) stock quote today ?
Annexin Pharmaceuticals AB (publ) stock price is $0.275 today.
Is Annexin Pharmaceuticals AB (publ) stock public?
Yes, Annexin Pharmaceuticals AB (publ) is a publicly traded company.
Company Profile
- Volume Average 397.9K
- Market Capitalization 95.31M
- Employee 4
- CEO Dr. Anders Haegerstrand M.D., Ph.D.
- Headquarters Stockholm,SE
- IPO Date 2017-04-19
-
Website
https://www.annexinpharma.com/sv 
Annexin Pharmaceuticals AB (publ), a biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. The company develops ANXV, a human recombinant protein. It offers Annexin A5 to protect and repair blood vessels and counteract inflammation. The company was founded in 2014 and is based in Stockholm, Sweden.
